SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SARS and Avian Flu
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Amy J who wrote (1717)10/6/2004 6:57:31 AM
From: Henry Niman  Read Replies (1) of 4232
 
My guess is that it will be first come first served (for high risk patients). Initially there should be stocks available because AVE is shipping on schedule. There are more companies that make vaccine overseas (I think there are 6 manufaturers for Europe) and I think the actual vaccine components are the same for all providers (only flumist is in the form of a nasal spray).

If others can boost production (although it is late to get started for this season), I suspect the FDA could decalre some sort of health emergency and approve the sale of vaccine manufactured by others (after some quick safety checks or allow the other countries to use safety data generated overseas).

I don't know how tight the supply is, but I doubt that anything will come from CHIR and I don't expect more than 54 million doses from AVE.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News